By the Top Tier Newswire AI Desk · August 6, 2026 at 12:10 AM ET · reviewed against 7 wire stories
UROGEN PHARMA LTD (URGN) is up +16.31% in the latest session. Our newswire has captured 7 stories on URGN across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why URGN stock is up today
UroGen Pharma stock surged 16.31% to $46.43 in intraday trade on August 5, 2026, driven by a strong earnings report and positive guidance. The company reported second-quarter revenue of $72.5 million, exceeding estimates by $8.96 million, with ZUSDURI revenue alone reaching $50.4 million, up 73% quarter-over-quarter. The stock also benefited from a new patent extension for ZUSDURI, which now offers protection through 2044, reinforcing the company's long-term growth potential.
What Happened
UroGen posted a standout second quarter with ZUSDURI revenue jumping 73% to $50.4 million, supported by strong clinical data and expanded adoption. The company also provided updated 2026 operating expense guidance of $260 million to $270 million. A new U.S. patent for ZUSDURI, supported by the ENVISION and ATLAS trials, was granted a notice of allowance by the U.S. Patent and Trademark Office, extending its exclusivity until 2044. The stock’s sharp rise also followed a GAAP loss of $0.28 per share, in line with expectations, and a 52.9% year-to-date revenue increase.
What The Data Shows
The stock’s 16.31% gain came on heavy volume, though no specific volume figure is provided. The 52-week range is $15.86 to $43.93, meaning the current price of $46.43 exceeds its recent high. UroGen remains unprofitable with a trailing twelve-month EPS of -2.73 and a net margin of -94.8%. The company’s market cap is $1.9 billion, and it carries a beta of 1.57, indicating higher volatility than the broader market. In the past 90 days, insiders have sold a total of $1.2 million in shares, with the most recent filing on July 10.
What To Watch
UroGen has not announced an upcoming earnings date. Investors should monitor the breadth of analyst coverage and any further updates on ZUSDURI’s market performance and patent developments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call August 5, 2026 10:00 AM EDTCompany ParticipantsVincent Perrone - Senior Director of Investor...
5d agoMarketChameleonBULLISH 67Product/PR
ZUSDURI Revenue Surges 73% at UroGen: New Patent Strengthens Long-Term Outlook
August 5, 2026
UroGen Pharma posted robust second-quarter growth with ZUSDURI revenue climbing to $50.4 million, up 73% quarter-over-quarter. Patent developments, strong clinical data, and a deep pipeline set the stage for long-term advancement despite continued operating losses.
5d agoMarketChameleonBULLISH 67Product/PR
UroGen’s ZUSDURI Revenue Surges 73% with Patent Extension Poised to Bolster Franchise Through 2044
August 5, 2026
UroGen Pharma posts a standout second quarter with ZUSDURI revenue jumping 73%, reinforced by strong clinical durability and a new US patent set to protect its leading bladder cancer therapy for nearly two decades. The company's growing portfolio and expanding clinical trials signal a durable growth trajectory despite ongoing losses.
5d agoSeeking AlphaBULLISH 56Earnings
UroGen Pharma GAAP EPS of -$0.28 in-line, revenue of $72.5M beats by $8.96M; updates FY outlook
UroGen Pharma press release (URGN): Q2 GAAP EPS of -$0.28 in-line. Revenue of $72.5M (+199.6% Y/Y) beats by $8.96M.
5d agoSEC 8-KNEUTRAL 50General
UroGen Pharma Ltd. (URGN) files 8-K
Filed: 2026-08-05 AccNo: 0001437749-26-025793 Size: 267 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
5d agoBusiness InsiderBULLISH 63Earnings
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →